Sanofi, Minapharm Ink Deal for Localizing the Manufacture of Clexane

Sanofi and Minapharm signed an exclusive manufacturing and supply agreement for the localization of the full range of its flagship product, Clexane.

The agreement boosts Egypt’s national localization strategy of biopharmaceutical manufacturing. Localizing the manufacturing of Sanofi’s Clexane adapts to changing market dynamics and enhances industrial innovative technologies.

The manufacturing of Clexane will take place in Minapharm’s new state-of-the-art biopharmaceutical facility in Egypt dedicated to research, development, and manufacture of complex bioengineered proteins.

Ahmed Raouf, managing director and chairperson of Sanofi Egypt said, “This agreement affirms Sanofi Egypt’s pledge to support the localization plan of pharmaceutical and biological industries in Egypt by transfer of advanced manufacturing technology in cooperation with distinctive industry partners. This event comes as a continuation of efforts to provide essential and modern treatments to the Egyptian patient.”

Wafik Bardissi, Chairman and CEO of Minapharm said, “This partnership with Sanofi corroborates the common national health policy directives with the commitment of both parties to ensure elevated patient access to essential complex biologics. It further complements the local, regional and global technology contribution of Minapharm and its European subsidiaries to the world’s bio-industry.”